Table 1.
Clinical and demographic characteristics of the included patients (mean ± SD)
| Patient characteristics | Treated (n = 7) | Untreated (n = 6) | P vaule |
| Age (yr) | 50.0 ± 14.6 | 45.0 ± 13.6 | 0.540 |
| Gender (male/female) | 4/3 | 3/3 | 0.400 |
| Extent of disease | |||
| Pancolitis | 6 | 5 | 0.540 |
| Left- sided | 1 | 1 | 0.540 |
| Age on diagnosis of UC, yr | 35.7 ± 13.3 | 41.5 ± 13.3 | 0.530 |
| Duration of disease, yr | 14.2 ± 9.3 | 3.5 ± 1.8 | 0.008 |
| Hospitalized patients | 6 | 4 | 0.560 |
| Prehospitalization treatment | |||
| SC | 4 | 2 | 0.560 |
| Thiopurines | 3 | 2 | 1.000 |
| Infliximab | 11 | 0 | 1.000 |
| 5-asa | 5 | 4 | 1.000 |
| SC + thiopurines | 2 | 1 | 1.000 |
| Treatment during hospitalization | |||
| SC | 6 | 3 | 0.400 |
| Infliximab | 1 | 0 | 1.000 |
| Cyclosporine | 3 | 0 | 0.200 |
| Timing of colonoscopy (d) | 3.8 ± 2.4 | 2.7 ± 3.4 | 0.600 |
| Positive cytopathic changes on HE | 2 | 0 | 0.460 |
| Hospitalization outcome | |||
| Death | 1 | 0 | 1.000 |
| Colectomy | 1 | 0 | 1.000 |
| Outcome by the of the follow-up | |||
| Colectomy | 3 | 0 | 0.190 |
| Death | 1 | 0 | 1.000 |
1Combined with systemic corticosteroids and thiopurine. Treated: Patients who received antiviral therapy; Untreated: Patients who did not receive antiviral therapy; Timing of colonoscopy: Number of days from hospital admission; SC: Systemic corticosteroids; HE: Hematoxylin eosin; IHC: Immunohistochemistry; UC: Ulcerative colitis.